ICAP

PURPOSE 4/HPTN 103 Study

A Phase 2, open-label, multicenter, randomized study to evaluate the pharmacokinetics and safety of twice-yearly long-acting subcutaneous lenacapavir for pre-exposure prophylaxis in people who inject drugs.


https://www.avac.org/trial/purpose-4-hptn-103

Status

Coming

Locations

Our Approach

Research

Health Challenges